Botensilimab is under clinical development by Agenus and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Botensilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Botensilimab overview

AGEN-1181 is under development for the treatment of solid tumors including angiosarcoma and microsatellite stable tumors but not limited to PD-1-refractory non-small-cell lung cancer, ovarian cancer and melanoma, MSS-colorectal cancer, renal cell carcinoma, endometrial cancer, cervical cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, leiomyosarcoma and colorectal cancer. The therapeutic candidate is administered through intravenous route. It is developed based on retrocyte display technology. The therapeutic candidate acts by targeting cytotoxic T lymphocyte-associated molecule-4 (CTLA-4).

Agenus overview

Agenus is a clinical-stage immuno-oncology company that discovers, develops, and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as GSK, Incyte, and Merck. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Botensilimab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.